New Leadership Presents “Good Opportunity” to Expand Community-Based Trials

Commentary
Video

START is the largest early-phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, PhD, MRCPI.

In a conversation with CancerNetwork®, Geraldine O’Sullivan Coyne, MD, PhD, MRCPI, spoke about her new appointment as the principal investigator and director of clinical research at the Northwell Health unit of the Southern Texas Accelerated Research Therapeutics (START) Center for Cancer Research. Following a strategic partnership formed between Northwell Health and START in May 2024, Coyne will oversee early-phase clinical trials at New York’s first START research site at the R.J. Zuckerberg Cancer Center in New Hyde Park.

According to Coyne, the new position has offered her a “moment of delight” as well as an opportunity to expand clinical trial enrollment among patients with cancer who reside in community settings. Additionally, she highlighted the history behind START’s formation, which she described as the largest early-phase oncology network in the community setting.

Transcript:

It has truly been a moment of delight for me and one that has been a proud moment, personally. It is, however, incredibly humbling to have been offered this opportunity, one that I am looking forward to putting in all my efforts [and] making this, hopefully, a good opportunity for patients to be able to be considered for trials within the community [while] partnering, in this sense, with Northwell Health here at their Long Island campus.

START stands for Southern Texas Accelerated Research Therapeutics, and it was founded in 2007 by a group of oncologists in the locality that were interested in [bringing] these types of trials into their community. START, since then, has had an increasingly well-recognized record both in the US as well as in Europe. It is now the largest early-phase oncology network in the community, globally. This is by a variety of metrics, including the number of physicians that are dedicated [to] START, principal investigators or PIs, as well as the extent and the locality of the START networks to date.

Reference

Olt B. Northwell names Geraldine O’Sullivan Coyne, MD, PhD, to lead clinical trials at new START center. News release. Northwell Health. July 22, 2025. Accessed August 7, 2025. https://tinyurl.com/bdcua8ck

Recent Videos
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Related Content
The Nuclear Medicine Clarification Act seeks to increase transparency in reporting potentially high-dose extravasations in administering radiation.

H.R. 2541: Examining Its Legislative Impact on Radiopharmaceutical Practice

Roman Fabbricatore
October 30th 2025
Article

The Nuclear Medicine Clarification Act seeks to increase transparency in reporting potentially high-dose extravasations in administering radiation.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Assessment of ZEN-3694 plus abemaciclib or cisplatin/etoposide in NUT carcinoma is ongoing across 2 active clinical trials.

ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma

Russ Conroy
October 29th 2025
Article

Assessment of ZEN-3694 plus abemaciclib or cisplatin/etoposide in NUT carcinoma is ongoing across 2 active clinical trials.

How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.

ESMO Congress 2025 included a variety of presentations that may change the treatment paradigm in lung cancer, breast cancer, and other types of disease.

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

Russ Conroy
October 24th 2025
Article

ESMO Congress 2025 included a variety of presentations that may change the treatment paradigm in lung cancer, breast cancer, and other types of disease.

Medical Conference Forum Latest Advances in Healthcare | © Purnomo-Adobe Stock

The Fellow's Playbook: How to Make the Most of Your First Oncology Meeting

Ariana Pelosci
October 21st 2025
Article

Third-year fellows from Weill Cornell Medicine offer 7 key tips for establishing a foundational understanding of the field at major oncology meetings.